Manufacturing

Grand River Aseptic Manufacturing has completed phase II of its facility expansion with the installation of two new sterile filling lines.

ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate.

Validair Diamond Scientific has installed a new cleanroom for in-house testing, research, and training.

Guest contributor B.S. Sathya Durga discusses the importance of modernizing India's pharmaceutical manufacturing industry.

The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.

The new facility in Albany, Ore., will support biopharmaceutical development and lyophilization services.

Experts divulge where the industry is outsourcing most frequently, when companies should outsource more, and when performing tasks in-house might be best.

The growth in demand of viral-vector-based gene therapies drives continuous efforts to improve viral vector manufacturing.

Automation enables intensification of downstream processes.

Successful scale-up and BLA filings for products manufactured by microbial biomanufacturing require strategic planning.

This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.

Manufacturers are taking the first steps toward process intensification.

DuPont’s new manufacturing site will expand its biopharmaceutical tubing manufacturing capabilities.

WuXi STA is opening a new large-scale oligonucleotide and peptide manufacturing facility.

Guest contributor Frederic Kahn discusses the state of the Indian pharmaceutical manufacturing industry.

TFF Pharmaceuticals is expanding its R&D operations with a new facility in Austin, Texas.

Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment.

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.

Croda has entered into an agreement with the US government to support the expansion of its lipid systems capability.

VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.

Automation and digitalization work together in the digital plant.

The business impact of modeling and simulation tools is not well understood and requires clarification of their benefits to drug development.

Finding specific solutions to overcome uncertainty has led to the evolution of a new clinical trial research environment.

Industry adoption of plant-made biologics remains slow, but plant-based technology gains an advantage by mainstream exposure.